Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Clinical Trials01:16

Clinical Trials

6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.6K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

612
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
612
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.3K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.3K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.2K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial.

Breast cancer (Tokyo, Japan)·2026
Same author

Interictal thalamocortical network configuration is associated with susceptibility to seizure-related impaired consciousness in focal epilepsy.

NeuroImage·2026
Same author

Pre-weekend effect in pulmonary resection for non-small cell lung cancer: a multicenter retrospective cohort study.

Surgery today·2026
Same author

Remote Self-help cognitive-behavioural Therapy for irritable bowel syndrome (ReSeT): protocol for a randomised controlled trial.

BMC gastroenterology·2026
Same author

Experienced stigma in Japanese outpatients with diabetes: Age and polypharmacy matter.

Medicine·2026
Same author

Dynamic Prediction of Analysis Timing in Clinical Trials Using Joint Models of Longitudinal and Time-to-Event Data.

Statistics in medicine·2025

Related Experiment Video

Updated: Aug 12, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.9K

Optimal dose escalation methods using deep reinforcement learning in phase I oncology trials.

Kentaro Matsuura1, Kentaro Sakamaki2, Junya Honda3

  • 1Department of Management Science, Graduate School of Engineering, Tokyo University of Science, Tokyo, Japan.

Journal of Biopharmaceutical Statistics
|January 31, 2023
PubMed
Summary

This study introduces a deep reinforcement learning method to improve the selection of the maximum tolerated dose (MTD) in early-phase cancer drug trials. The novel approach significantly enhances the percentage of correct MTD selection compared to existing methods.

Keywords:
Adaptive designClinical trialDose-findingMaximum tolerated doseOptimal design

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Related Experiment Videos

Last Updated: Aug 12, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Artificial Intelligence

Background:

  • Identifying the maximum tolerated dose (MTD) is critical in phase I clinical trials for novel anticancer drugs.
  • Existing MTD-finding methods often show insufficient percentages of correct selection (PCS), hindering dose determination for later trial phases.

Purpose of the Study:

  • To develop an advanced action rule for dose escalation/de-escalation and trial continuation/stopping.
  • The goal is to maximize the percentage of correct MTD selection (PCS) in phase I trials.

Main Methods:

  • Utilized deep reinforcement learning (DRL) to construct an adaptive action selection rule.
  • Defined specific states, actions, and reward functions tailored for MTD identification.

Main Results:

  • The DRL-based method demonstrated improved PCS compared to traditional designs.
  • Simulations showed superior performance against 3+3, CRM, BLRM, BOIN, mTPI, and i3+3 designs.

Conclusions:

  • Deep reinforcement learning offers a powerful framework for optimizing MTD selection in early-phase oncology trials.
  • The proposed DRL strategy enhances the reliability of MTD identification, potentially improving subsequent trial phases.